Industry News
Biotechnology Industry News
Novartis has reported a phase 1/2…
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for
Over-the-counter drugmaker Perrigo…
Over-the-counter drugmaker Perrigo Company is washing its hands of chief executive Patrick Lockwood-Taylor, who resigned from his post of president and CEO after the company’s board of directors found “certain personal conduct” by Lockwood-Taylor inconsistent with
Genentech vice presidents Vishva…
Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of
Kardigan has sewn up its IPO…
Kardigan has sewn up its IPO plans, with the cardiovascular biotech expecting to bring in a cozy $320 million from its planned Nasdaq listing.
Caribou Biosciences has linked its…
Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival, adding to evidence that the off-the-shelf treatment can match the efficacy of autologous products in lymphoma patients.
Fierce Biotech is returning to the…
Fierce Biotech is returning to the U.K. in November for a day of curated discussions and networking at The Savoy, London’s iconic hotel.
Takeda has won the battle of the…
Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.
Christelle Huguet, Ph.D.,…
Christelle Huguet, Ph.D., Ipsen’s executive vice president and head of R&D, sits down with Fierce Healthcare & Life Sciences Editor-in-Chief Ayla Ellison to discuss pipeline discipline, external partnerships and key 2026 milestones.
Neoantigen-based therapies are…
Neoantigen-based therapies are considered one of the most promising approaches in modern immuno-oncology. One challenge continues to limit the field: accurately identifying which neoantigens will generate meaningful anti-tumor immunity.
Even as industry watchers pit the…
Even as industry watchers pit the two assets against one another, it’s too early to say whose next-generation incretin stands supreme between Novo Nordisk’s CagriSema and Eli Lilly’s retatrutide, Novo’s chief scientific officer suggested to
Bay Area biotech SonoThera is…
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma.
Ethyreal Bio has exited stealth…
Ethyreal Bio has exited stealth with $101 million, joining the queue of companies preparing to challenge Amgen’s Tepezza.
Parabilis Medicines’ IPO has…
Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the biotech sector’s history.
Sanofi has stopped a phase 3…
Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key late-phase program and continues
As understanding of rare…
As understanding of rare cholestatic liver diseases has evolved, endpoint science and patient engagement may help shape future PSC research.
Executives told Fierce how the…
Executives told Fierce how the company is in the middle of a transition to “the new Biogen”—embracing partnerships, investment and entrepreneurship to replenish its pipeline.
Mere months after obesity biotech…
Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to
Eli Lilly has signed a heavily…
Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.
With a pair of phase 2 readouts,…
With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal studies.
Biotech’s effervescent activity…
Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital